Hsbc Holdings PLC boosted its holdings in shares of Revvity Inc. (NYSE:RVTY - Free Report) by 25.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 177,678 shares of the company's stock after acquiring an additional 36,050 shares during the quarter. Hsbc Holdings PLC owned approximately 0.16% of Revvity worth $19,762,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in RVTY. Ascentis Independent Advisors acquired a new position in shares of Revvity during the 1st quarter worth $29,000. CYBER HORNET ETFs LLC acquired a new stake in shares of Revvity in the 2nd quarter valued at $32,000. MUFG Securities EMEA plc acquired a new stake in shares of Revvity in the 2nd quarter valued at $34,000. SJS Investment Consulting Inc. boosted its holdings in Revvity by 5,210.0% in the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company's stock worth $47,000 after purchasing an additional 521 shares in the last quarter. Finally, Headlands Technologies LLC bought a new stake in Revvity in the second quarter worth $49,000. 86.65% of the stock is currently owned by institutional investors and hedge funds.
Revvity Stock Performance
RVTY opened at $127.45 on Wednesday. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36. The stock's 50 day moving average price is $117.12 and its two-hundred day moving average price is $102.75. The firm has a market capitalization of $14.22 billion, a P/E ratio of 60.69, a price-to-earnings-growth ratio of 2.37 and a beta of 1.09. Revvity Inc. has a 12-month low of $81.22 and a 12-month high of $133.00.
Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.21 by $0.20. The company had revenue of $729.69 million during the quarter, compared to analyst estimates of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The company's quarterly revenue was down 1.3% compared to the same quarter last year. During the same period in the previous year, the company earned $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts forecast that Revvity Inc. will post 5.37 earnings per share for the current year.
Revvity Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be issued a $0.07 dividend. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. Revvity's dividend payout ratio is 13.33%.
Wall Street Analyst Weigh In
RVTY has been the topic of several recent research reports. Zacks Research upgraded Revvity from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 4th. Evercore reiterated an "outperform" rating on shares of Revvity in a research note on Wednesday, August 5th. Royal Bank Of Canada began coverage on Revvity in a report on Tuesday, September 1st. They set a "sector perform" rating and a $135.00 price objective on the stock. TD Cowen restated a "buy" rating on shares of Revvity in a report on Wednesday, July 15th. Finally, KeyCorp upped their target price on Revvity from $125.00 to $165.00 and gave the stock an "overweight" rating in a research report on Friday. Four equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $114.77.
Read Our Latest Research Report on Revvity
Revvity Company Profile
(
Free Report)
Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.
Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.
Featured Stories
Want to see what other hedge funds are holding RVTY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revvity Inc. (NYSE:RVTY - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Revvity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revvity wasn't on the list.
While Revvity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
